Spero Therapeutics Inc (NASDAQ:SPRO) Expected to Announce Quarterly Sales of $3.54 Million
Equities research analysts predict that Spero Therapeutics Inc (NASDAQ:SPRO) will announce sales of $3.54 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Spero Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.37 million. Spero Therapeutics reported sales of $1.69 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 109.5%. The company is scheduled to report its next earnings report on Thursday, March 12th.
According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $18.05 million for the current fiscal year, with estimates ranging from $16.50 million to $19.89 million. For the next financial year, analysts expect that the company will post sales of $14.12 million, with estimates ranging from $8.40 million to $19.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.10). The business had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%.
Shares of SPRO traded up $0.17 during mid-day trading on Monday, reaching $11.09. The company’s stock had a trading volume of 59,684 shares, compared to its average volume of 48,266. The business has a fifty day moving average of $10.99 and a 200 day moving average of $10.85. The company has a market cap of $210.60 million, a price-to-earnings ratio of -4.27 and a beta of 2.10. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.
Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Novo Holdings A S acquired a new position in shares of Spero Therapeutics in the second quarter worth $5,363,000. BlackRock Inc. increased its stake in shares of Spero Therapeutics by 56.0% in the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock worth $7,559,000 after acquiring an additional 235,691 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Spero Therapeutics by 89.7% in the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock worth $2,474,000 after acquiring an additional 101,600 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of Spero Therapeutics by 6.4% in the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock worth $6,887,000 after acquiring an additional 36,019 shares during the last quarter. Finally, State Street Corp increased its position in Spero Therapeutics by 16.3% during the third quarter. State Street Corp now owns 197,226 shares of the company’s stock worth $2,091,000 after buying an additional 27,695 shares during the last quarter. 48.36% of the stock is currently owned by institutional investors and hedge funds.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
See Also: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.